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The overlap syndrome of obstructive sleep apnoea (OSA) and chronic obstructive pulmonary disease (COPD), in
addition to obesity hypoventilation syndrome, represents growing health concerns, owing to the worldwide COPD
and obesity epidemics and related co-morbidities. These disorders constitute the end points of a spectrum with distinct
yet interrelated mechanisms that lead to a considerable health burden. The coexistence OSA and COPD seems to occur
by chance, but the combination can contribute to worsened symptoms and oxygen desaturation at night, leading to
disrupted sleep architecture and decreased sleep quality. Alveolar hypoventilation, ventilation-perfusion mismatch and
intermittent hypercapnic events resulting from apneas and hypopneas contribute to the final clinical picture, which is
quite different from the “usual” COPD. Obesity hypoventilation has emerged as a relatively common cause of chronic
hypercapnic respiratory failure. Its pathophysiology results from complex interactions, among which are respiratory
mechanics, ventilatory control, sleep-disordered breathing and neurohormonal disturbances, such as leptin resistance,
each of which contributes to varying degrees in individual patients to the development of obesity hypoventilation.
This respiratory embarrassment takes place when compensatory mechanisms like increased drive cannot be maintained
or become overwhelmed.
Although a unifying concept for the pathogenesis of both disorders is lacking, it seems that these patients are in a
vicious cycle. This review outlines the major pathophysiological mechanisms believed to contribute to the
development of these specific clinical entities. Knowledge of shared mechanisms in the overlap syndrome and obesity
hypoventilation may help to identify these patients and guide therapy.
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Over recent decades, our understanding of the mecha-
nisms leading to sleep disordered breathing has steadily
improved, with most studies focussing on ventilatory
control mechanisms and upper airway patency during
sleep. Instability of the breathing pattern can go along
with an increase in upper airway resistance, increased
collapsibility of the upper airway and poor coordination
of local reflex mechanisms, which can result in obstructive
apneas [1]. Interaction between obstructive sleep apnea
(OSA), and a number of different distinct clinical cat-
egories, like COPD, chronic heart failure, neuromuscular
disorders and obesity, can lead to more complex disorders,
with complications sharing common pathways [1-3]. In* Correspondence: johan.verbraecken@uza.be
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distribution, and reproduction in any mediumobese subjects, respiratory system mechanics can become
disturbed, in isolation or in association with upper airway
pathology, and obesity hypoventilation syndrome (OHS)
may develop as a result [4-6]. According to the Inter-
national Classification of Functioning, OHS is a chronic
condition associated with respiratory, metabolic, hormonal
and cardiovascular impairments, leading to a decrease in
daily life activities, a lack of social participation and a
high risk of hospitalisation and death (Figure 1) [7].
OSA and COPD are both prevalent disorders [8-10],
which are gaining more importance, due to the obesity
epidemic in Western countries [11,12] in addition to
smoking behaviour over previous decades [13]. The
World Health Organisation (WHO) predicts that around
10% of the global population will be obese by 2015
[11,12]. Patients who share both disorders have inspiratory
flow limitation on the one hand (OSA), and expiratory
flow limitation on the other hand (COPD) [3,14]. ThisBioMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.























Figure 1 Central and peripheral consequences of obesity (statue of Bachus in Boboli Gardens, Firenze, Italy).
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sleep more than in stand alone disorders, with an accu-
mulation of health risks and complications [15-17].
In this review we would like to address the patho-
physiological interactions between COPD, sleep and
OSA in the overlap syndrome as well as the mechanisms
involved in the pathogenesis of OHS. Both OSA and OHS,
besides central sleep apnea, take part of the spectrum
of sleep-disordered breathing [18,19], with preserved or
enhanced chemical drive on the one hand, and blunted
chemical drives on the other hand. The majority of
these patients presents with obesity. However, they are
also quite distinct from each other in a sense that obesity
is not always present in overlap syndrome, and chemical
drive can be preserved, while OSA is not always present
in obesity hypoventilation, and COPD is an exclusion
criterion in the definition of OHS. Therefore, it was
preferred to discuss them separately.
Overlap syndrome
Extent of the problem
Obstructive sleep apnea syndrome and chronic obstructive
pulmonary disease (COPD) are two diseases that often
coexist within an individual. This coexistence is referred
to as the overlap syndrome and is the result of chance
rather than a pathophysiological link. Previous studies
have suggested that the prevalence of OSA in patients
with COPD, and COPD in patients with OSA, was
high, sometimes unexpectedly high [20-23]. It has beenbelieved that the presence of COPD could predispose
to the development of OSA, since the two conditions
share some etiologic factors such as tobacco smoking.
This remained an unresolved question up to very recent
years. In 2003 the Sleep Heart Health Study provided
solid epidemiologic data about the coexistence of COPD
and OSA [24]. Participants with obstructive airway disease
had significantly lower mean and median RDI than
those without obstructive airway disease. However,
after stratification by BMI quartile, RDI values were
similar in the participants with and without obstructive
airway disease.
We presently know that the prevalence of COPD is
over 10% in adults 40 years of age or older, and may
exceed 20% [9,10,25]. Accordingly, it does not appear
that the prevalence of COPD is increased in patients
with OSA, when compared with the general population.
If COPD is present in about 10% of the adult popula-
tion 40 years of age or older, and if the prevalence of
OSA in the same population is in the range of 5 to
10%, overlap syndrome can be expected to be present
in 0.5 to 1% of the general population over 40 years of
age, which represents a relatively prevalence [3]. The
prevalence of COPD Gold stage III and IV, wherein
chronic or intermittent hypoxemia and hypercapnia are
more common, is in the range of 3% to 4% and likely
represents the segment of the COPD population that
can develop severe cardiopulmonary complications if
coincidence with OSA [14,26].
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Overlap patients present sleep-disordered breathing
associated to upper and lower airway obstruction and
a reduction in respiratory drive. These patients present
unique characteristics, which set them apart from either
COPD or OSA patients. The overlap population tends
to be older than the simple OSA population, with more
frequent hypoxemia and hypercapnia, higher mean
pulmonary artery pressures, but similar BMI [2]. Resta
et al. showed that overlap patients had higher PaCO2,
as well as similar AHI compared to OSA patients
without COPD [27]. O’Brien and Whitman found that
overlap patients were older and less obese than isolated
OSA controls [28].
Association with body mass index and smoking
Several confounding factors may influence relationships
between OSA and COPD, particularly smoking and BMI.
Obesity is a cardinal feature in OSA, while low BMI is
common in COPD, especially in patients with advanced
disease [24,29]. This feature may protect against OSA, and
is supported by the finding of a lower AHI in subjects with
airflow obstruction, relating to lower BMI [30]. However,
many other patients with COPD have elevated BMI,
thus predisposing to OSA, and the finding of a higher
AHI in overweight patients with airflow obstruction
supports this possibility [24]. Smoking is a risk factor
for OSA and COPD, and several reports found a higher
AHI in smokers than nonsmokers [31]. In the Wisconsin
Sleep Cohort Study it was found that an AHI of at least 5/
hour was three times more likely in current smokers
than in never-smokers. Heavy smokers (≥40 cigarettes/
d) had an OR of 6.74 for AHI of at least 5/hour [32].
Cigarette smoking predisposes to OSA by increasing
upper airway resistance due to local inflammation and
edema [33]. Altogether, it seems that in the majority of
the patients both obesity and smoking play an important
role in the genesis of overlap syndrome.
Alterations in respiratory mechanics and ventilatory control
during sleep related to COPD
Similar changes in respiratory function occur during sleep
in patients with COPD as in healthy subjects, independent
of OSA, although some can be more profound in COPD
and are related to accentuated physiological adaptations,
like hypoventilation [34,35] (Figure 2). It was shown
that in patients with COPD, respiratory control centre
output was reduced and upper airway resistance was
increased, both most pronounced during REM sleep
[36]. The circadian variation in airflow is exaggerated
in patients with COPD [37-39], with a mean daily change
in FEV1 and FVC of 30%. Moreover, the physiologic
hypoventilation normally present during sleep is accen-
tuated, resulting in greater falls in SaO2 during sleep,with associated hypercapnia. This is likely a result of
the increased physiologic dead space in COPD that
leads to an even greater decrease in alveolar ventilation
with lower tidal volumes than in normal subjects. Because
many COPD patients have awake hypoxemia, they are
especially prone to nocturnal oxygen desaturation by being
on the steep portion of the oxyhemoglobin dissociation
curve [30,34]. In addition, there is reduced contractility
of skeletal muscles, which includes the accessory muscles
of respiration for adequate ventilation, and REM related
muscle paralysis may result in poor ventilation during
sleep. The function of the diaphragm is even more
decreased than in healthy subjects due to stretching
related to lung inflation, and therefore relatively inefficient
[40], thus necessitating an increased accessory muscle
contribution to breathing [41]. The relatively large
dependency on diaphragm function during sleep in
COPD, due to the accessory muscle weakness, and the
dominant diaphragmatic activity during REM sleep,
might explain why patients with loss of respiratory
muscle strength during REM sleep show nocturnal
oxygen desaturations [42]. In advanced COPD, skeletal
muscle atrophy and dysfunction is common, which
may further compromise the contribution made by
accessory muscles [29]. In addition, ventilation-perfusion
mismatch and a reduced FRC may also play a role in
nocturnal hypoxemia in COPD [43]. Taken together,
accentuated physiologic hypoventilation, increased phy-
siologic dead space, lower awake oxygen levels, reduced
contractility of respiratory muscles, lung inflation,
(respiratory) muscle atrophy and ventilation-perfusion
mismatch contribute to a certain extent to alterations
in the ‘COPD’ component of the overlap syndrome.
Pathophysiological interactions between OSA and COPD
Several pathophysiological factors have been identified
which influence the relationship between OSA and
COPD. COPD-related factors that may predispose to
OSA include rostral shift of peripheral edema when
supine, resulting in fluid accumulation in the neck, thus
contributing to pharyngeal narrowing [44]. Although
no evidence is available in COPD, it might be particulary
expected in patients with cor pulmonale, among whom
peripheral edema is a major feature [45]. Peripheral edema
can be present in the absence of right heart failure in
COPD and is not diagnostic of cor pulmonale [46]. The
pathogenesis of edema formation in COPD is complex.
Renal blood flow is reduced, the renin-angiotensin system
is activated, leading to increase in proximal renal tubular
sodium reabsorption. Sodium retention is enhanced by
hypercapnia and ameliorated by long-term oxygen therapy
in hypoxemic patients [47]. As discussed earlier, BMI
and smoking also affect pathophysiological relationships.
Neck obesity contributes to upper airway narrowing,
nocturnal 
respiratory drive(supine) FRC













Figure 2 Mechanisms through which COPD and OSA interact during sleep.
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such narrowing has been related to nocturnal oxygen
desaturation in COPD, independent of OSA [48]. A
role could also be attributed to central obesity, which
predisposes to OSA [49]. Its mechanical impact will be
discussed in the obesity hypoventilation section. Finally,
use of corticosteroids may influence interactions between
COPD and OSA by promoting central obesity and fluid
retention with associated upper airway narrowing, in
addition to myopathy and metabolic alkalosis [30]. Among
all these factors, it could be assumed that central obesity
is the strongest predictor.
Ventilatory control in overlap
Very few studies have evaluated ventilatory control in
overlap syndrome [50,51]. Radwan et al. [50] reported a
higher breathing frequency and a lower tidal volume in
overlap compared to OSA patients. OSA patients presented
similar values to controls in awake ventilatory response
to CO2 and occlusion pressure responses, while overlap
patients had both blunted ventilatory responses and mouth
occlusion pressure responses to CO2. The ventilatory
responses could be disturbed by lung mechanics and
gas exchange. In subjects with chronic hypercapnia,
there is an increased blood bicarbonate concentration,
which may inhibit the ventilatory response to CO2 and
decreases mouth occlusion pressure response during
wakefulness and sleep [50].When normocapnic, overlap patients can however
have a normal or even enhanced ventilatory response
to CO2 [51]. This is in contrast to the data on decreased
hypercapnic (HCVR) and hypoxic (HVR) ventilatory
response in OHS, as compared to obese, non-hypercapnic
subjects [52]. Thus, obesity seems to be associated with
compensatory mechanisms. If they fail, OHS may appear.
Others have hypothesized that hyperinflation of the
lung may also decrease mouth occlusion response [53].
During sleep factors related to decreased mouth occlusion
pressure are respiratory muscle fatigue, related to the
mechanical disadvantage of chest wall hyperinflation,
and reduced FRC, related to supine posture and sleep
state, as discussed earlier (Figure 2). Hypoxemia and
hypercapnia are however less severe in patients with
overlap than in patients with OHS [54]. Altogether, the
wide range in chemical drives illustrates the existence of
different phenotypes in overlap patients, but also reflects
a gradual adaptation of chemoreceptors secondary to
mild elevation of serum HCO3- that can occur even
during acute hypercapnia.
Pathophysiological consequences
Data about the complications of overlap syndrome are
scarce, particularly for those patients who have less
severe COPD. Currently, it is unclear if patients who have
mild COPD are at risk for the same early complications
as those who have more severe disease. Similarly, the
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it relates to complications, course, and prognosis of the
disease. Research in this area suffers from the so-called
“iceberg phenomenon”, a metaphor emphasising that
for virtually every health problem the number of known
cases of disease is outweighed by those that remain
undiscovered. Close to this is the “clinician fallacy”, in
which an inaccurate view of the nature and causes of a
disease results from studying the minority of cases of the
disease that are seen in clinical treatment settings [55].
Disturbed sleep quality
Subjects with the overlap syndrome have higher Epworth
sleepiness scores, lower total sleep time, lower sleep
efficiency, and a higher arousal index compared with
those with COPD alone [24]. However, there was only
a small difference between those with OSA alone and
those with the overlap syndrome. It seems that in
patients with mild COPD, there is little effect on sleep
quality. As COPD becomes more severe, however, there
are increased sleep complaints. In addition, when OSA is
superimposed on COPD, there are more sleep complaints
and possibly more deleterious physiologic effects [37].
Recently, Kwon et al. reported that increased severity of
hyperinflation, which is the ratio of inspiratory capacity to
total lung capacity (IC/TLC), is associated with worse
sleep efficiency in overlap, independent of apnea and
nocturnal hypoxemia [56,57]. The mechanisms underlying
this observation are uncertain, and the relationship
was also preserved after controlling for bronchodilator
medications. A potential mechanism for this association
includes increased work of breathing due to lung
hyperinflation, which, in turn, leads to greater difficulty
with sleep onset and more sleep disturbances. Close to this
observation, significantly elevated St. George Respiratory
Questionnaire scores for total score and for each of
the three components have been reported in overlap
patients, as compared with patients who had isolated
COPD [58]. Altogether, sleep disturbance is related to
the relative contribution of each component of the
overlap syndrome, whereas sleep fragmentation is most
related to the severity of OSA.
More profound nocturnal oxygen desaturations and
CO2 desensitisation
The worsening hypoxemia seen at night in COPD
patients who do not have OSA is attributable to a
combination of alveolar hypoventilation and ventilation-
perfusion (V/Q) mismatch. Typically, these patients
present with a pattern of chronic hypoxemia. Alveolar
hypoventilation represents the predominant mechanism,
especially when individuals are in REM sleep in which
hypoventilation is common in normal controls [14].
Hypoxemia is also well described in OSA (Figure 2),but in this category, patients present with a pattern of
intermittent hypoxemia. The hypoxemic events in these
subjects are closely associated with apneas and hypopneas,
and result from alveolar hypoventilation. Individuals with
OSA have a normal oxygen saturation between respiratory
events, unless significant V/Q mismatch or shunting takes
place. Although a pathologic link between the two diseases
may not exist, it is clear that when they coexist, patients
may display more severe nocturnal oxygen desaturations
and worsened sleep quality [21,24]. Oxygen saturation
between apneas may typically remain low in patients
with the overlap syndrome (and could be applied to
OHS as well), although occasionally it may occur as well
in other patients with severe OSA. Mechanisms through
which hypoxemia and hypercapnia persist between apneas
are complex, and include at least insufficient interapneic
ventilation and temporal V/Q mismatch [59]. Lower FRC,
and hence lower oxygen reserve, could explain, at least
partly, the lower oxygen levels in the different conditions
[60-62]. Hence, it follows that hypoxemia in patients
who have the overlap syndrome is more severe than
that seen in either individual syndrome. These patients
typically have baseline oxygen saturation values lower than
normal subjects, and the greatest predictor of nocturnal
hypoxemia is daytime hypoxemia [14]. Sanders et al. [24]
examined the degree to which COPD and OSA independ-
ently and jointly contribute to oxygen desaturation during
sleep. After adjusting for confounding factors, the OR for
nocturnal oxygen desaturation was considerably increased
in OSA. Bednarek et al. [63] compared polysomnographic
variables between overlap syndrome and OSA patients.
The overlap syndrome group had lower mean oxygen
saturation and spent more time in oxygen desaturation
than the OSA group.
A certain degree of hypercapnia occurs in normal
subjects during sleep. Minute ventilation and CO2 sen-
sitivity progressively decrease as the depth of sleep
increases. It was shown that the slope of the hypercapnic
ventilatory response decreases during NREM sleep and
is more blunted in REM sleep [64,65]. This finding results
from a change in the brainstem responsiveness to hyper-
capnia in NREM and REM sleep. COPD patients, having a
mechanical disadvantage to increase tidal volume due to
flattened diaphragms, demonstrate an altered hypercapnic
ventilatory response during sleep. Patients who have
coexistent OSA have repetitive acute hypercapnic events
resulting from apneas and hypopneas, leading to arousal
with stimulation to increase ventilation. When ventilation
is not much compromised, CO2 drive will be preserved,
and patients will remain normocapnic, while hypercapnia
will develop when blunting takes place [51,66,67]. More-
over, hypoxia may also affect HCVR, since it interferes
with synthesis and turnover of a wide range of neuro-
transmitters and shifts the slope of HCVR to the left.
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ventilatory responsiveness, leading to reduced ventilation
and reduced CO2 elimination, both between apneas and in
daytime [68]. Gold et al. suggested a reduction of HCVR
and HVR due to chronic hypoxemia, worsening apnea,
without recovery during wakefulness when oxygen was
administered [69]. Leech et al. associated an improvement
in oxygenation with a less depressed responsiveness of
control centers, ameliorating the severity of OSA [70].
Moreover, it was reported that hypercapnia could
develop in OSA in the absence of COPD [23], but also
in overlap syndrome independently of lung function
[71]. The observation that OSA patients with reduced
respiratory drive do not increase their ventilation when
terminating apnea could explain this development [72].
Effectively, daytime hypercapnia is more common in
overlap syndrome as compared to simple OSA [23].
However, a correlation between hypercapnia and the
frequency and duration of respiratory events during the
night could not be observed [72,73]. A progressive
resetting to a lower sensitivity threshold that occurs in
the central chemoreceptors could be involved. Chronic
stimulation bombarding the respiratory neuronal network
could reset the chemoreceptor threshold, that appears
over several years. The finding of an increase in slope
as well as a left shift of the HCVR after tracheostomy
could support this [74]. Finally, also constitutional or
genetic factors may be responsible for lowered HCVR
in hypercapnic patients [75]. Altogether, although recent
and in-depth studies in overlap syndrome are lacking,
available evidence supports more severe oxygen desatura-
tions, worsened sleep quality and CO2 desensitisation
as consequences of overlap syndrome. However, obesity
as a confounding factor, giving rise to CO2 alterations,
could not be excluded. This indicates that both syndromes
cannot be completely separated, but are classified artifi-
cially based on strict and rigid definitions.
Pulmonary hypertension
OSA and COPD have been associated with variable
degrees of pulmonary hypertension, defined as a mean
pulmonary arterial pressure of ≥20 mmHg, potentially
linked to the severity of disease. In one study [76],
pulmonary hypertension was found in 13.6% of OSAS
patients and in 80% of overlap patients. In another
study the prevalence of pulmonary hypertension was
36% in patients with overlap, much higher than in
usual OSA patients (9%), but somewhat lower than in
the OHS [54]. The mechanism of pulmonary pressure
elevation seems to be the relatively severe hypoxemia
and not the inflammatory aspect of COPD or OSA. In
general, subjects with COPD do not develop pulmonary
hypertension, unless they have severe airway obstruction
with substantial hypoxemia [77]. However, a small groupof COPD patients will develop severe or so called “out-
of-proportion” pulmonary hypertension, defined as a
mean pulmonary artery pressure above 40 mmHg [77].
In OSA, AHI was a weak predictor of pulmonary arterial
hypertension, whereas nocturnal oxygen desaturation
was a more significant determinant of the presence of
pulmonary hypertension. Subjects with the overlap syn-
drome can develop pulmonary hypertension with only
mild to moderate obstruction [3]. This may result from
the combined effects of both diseases contributing to
hypoxemia and effects on pulmonary hemodynamics,
with less of a contribution from the underlying mechanism
from COPD or OSA [42]. Mechanisms underlying these
interactions on the pulmonary vascular bed have further to
be unraveled. Anyway, pulmonary hypertension is highly
prevalent in overlap syndrome and seems more related
to the hypoxemia level than to the AHI.
Cardiovascular
COPD and OSA are independent risk factors for cardio-
vascular events and their coexistence in overlap syndrome
probably increases the risk. Shiina et al. reported an
increase in arterial stiffness and significantly higher
plasma BNP levels in subjects with overlap syndrome
than in those with OSA alone [78]. Overlap was also
associated with a markedly higher right ventricular mass
index and right ventricular remodelling index com-
pared to a COPD-only group [79]. Finally, among elderly
patients, the presence of overlap syndrome is associated
with a marked increase in risk of new onset atrial fibril-
lation as compared to the presence of OSA or COPD
alone [80]. The mechanisms underlying cardiovascular risk
are still unclear, but may involve systemic inflammation,
endothelial dysfunction, and tonic elevation of sympathetic
neural activity [2]. It is unclear whether the overlap
syndrome carries additive or synergistic consequences
of the inflammatory consequences of these two disorders.
There is evidence of increased circulating CRP and IL-6
levels in COPD whereas in OSA obesity is a major
confounding variable and the evidence of an independent
relationship between OSA and CRP/IL-6 levels is less
clear. Data also indicate an activation of TNF-α in COPD
and OSA with hypoxemia being the key factor. Oxidative
stress occurs in COPD and OSA and is associated with
an increased production of reactive oxygen species,
principally from leukocytes. However, confounding factors
such as cigarette smoking and obesity also promote
oxidative stress. Finally, there is evidence of activation/
dysfunction of circulating leukocytes in OSA and COPD,
which has particular relevance because leukocyte accu-
mulation and adhesion to the endothelium are of key
importance to atherosclerotic plaque formation [30].
Taken together, overlap syndrome has a substantial car-
diovascular burden, in line with the burden described
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overlap syndrome is effectively associated with more
inflammation, oxidative stress and activated cell lines
compared to isolated OSA or COPD is an unanswered
question. Again, an impact of obesity (hypoventilation)
cannot be ruled out.
Obesity hypoventilation syndrome
At the end of the spectrum of sleep-disordered breathing,
which starts with simple snoring and evolves into OSA
(eventually in association with COPD), OHS can be
found. OHS is commonly defined as a combination of
obesity (BMI ≥ 30 kg/mc) and awake arterial hypercapnia
(PaCO2 > 45 mmHg) in the absence of other known
causes of hypoventilation [4]. Patients are characterized
by a spectrum of findings: episodes of obstruction,
hypoventilation or sustained obstructive hypoventilation
due to partial upper airway obstruction [5]. We don’t
exactly know why some obese patients develop OHS, while
others do not, nor do we fully understand the etiology
of OHS, although it is almost certainly multifactorial in
nature [6]. Patients may complain of fatigue or daytime
sleepiness, but many remain asymptomatic with no sleep-
related complaints. Sleep hypoventilation alone does
not define OHS unless daytime hypercapnia is also
present. It was hypothesized that obese patients with
hypoventilation during sleep without awake hypercapnia
have a “prodromal” form of OHS and will later develop
chronic hypercapnia [81,82]. Some authors suggest that
OHS is a mixed disorder of “can’t breathe”(unable to over-
come impediments to breathing resulting from derange-
ments in lung function, the performance of the respiratory
muscles, and/or the mass loading effect of truncal obesity)
and “won’t breathe” (decreased ventilatory drive disorder)
[83-85]. Abnormal load responsiveness, ventilatory muscle
dysfunction, increased respiratory work and CO2 pro-
duction, impaired central respiratory drive and re-
peated airway obstruction during sleep are all possible
pathophysiological components in this entity, but the
precise contribution of each remains to be fully eluci-
dated [5,6,86,87]. Different responses to CPAP, BPAP or
NIV might reflect an intriguing possibility: the weight
of the different pathophysiological mechanisms may
vary in individuals with OHS. It seems that in some
patients, severe OSA might be a major contributor to
OHS pathophysiology, with respiratory system mechanics
playing only a minor role. These patients could be
successfully treated with long-term CPAP. On the
other hand, other patients might stand out as having
moderate or severe restrictive pulmonary defects and
considerable nocturnal oxygen desaturation with low
AHI values. These patients would require long-term NIV
or BPAP ST/T. Controlled pressure support/control is
necessary if CPAP fails [6,88-92].The incidence of OHS increases significantly as obesity
increases, with a reported prevalence of around 10 to
20% in outpatients presenting to sleep clinics [54,93-95]
to almost 50% of hospitalized patients with a BMI
greater than 50 kg/m2 [96]. Current estimates suggest
that around 0.15 to 0.4% of the population may have
OHS [97,98].
Development of obesity hypoventilation
There are clearly specific differences between obese in-
dividuals which determine that only some morbidly
obese subjects develop awake hypoventilation. The
mechanisms underlying the selective development of
awake hypoventilation is a major subject of interest in
respiratory sleep medicine. Various compensatory mecha-
nisms are adopted by morbidly obese subjects to maintain
eucapnia, despite chronically loaded breathing [82], but
are impaired or overwhelmed in OHS. The interactions
between the cardinal components of obesity and hypo-
ventilation are shown in Figure 3.
Ventilatory system mechanics
Obesity, particularly when it is severe, can be associated
with significant changes in pulmonary mechanics and
respiratory muscle performance. In simple obese, there
are also data which show that the mechanical influences
are of relatively low importance, with an approximate
0.5% decrease in VC, TLC, and RV with each unit increase
in BMI, and an approximately 1% decrease in FRC and
ERV for each unit increase in BMI [99]. However, many
of these effects are magnified in those obese patients
who develop OHS compared with equally obese individuals
either without or with sleep –disordered breathing
[27,100] (see Table 1). Obesity, with a higher degree of
central fat distribution, acts as a mass load on the
respiratory system [73], which implies both a weight
placed on the respiratory apparatus as well as an increase
in respiratory inertance [101-103]. Evidence exists that
a central pattern of fat distribution is predictive of the
impairments in pulmonary function more than BMI
[103]. This leads to a significant reduction in total lung
capacity, vital capacity, functional residual capacity, and
increases in residual volume [104]. Breathing at abnormally
low lung volumes changes the elastic recoil balance
between the chest wall and lung [105,106], and is asso-
ciated with increased lung resistance [107] and inspiratory
muscle strength [108,109]. Respiratory system compliance
has been shown to be around 20% less in eucapnic obese
subjects compared to individuals who are of normal
weight, and almost 60% less in patients with OHS
[110]. Breathing at low expiratory volumes signifies
breathing near the closing volume, and closure of the
most dependent airways and air trapping will occur,
resulting in expiratory flow limitation, microatelectasis and
Altered Respiratory Mechanics












Figure 3 Interactions between the cardinal components of obesity and hypoventilation.
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pressure (PEEPi) [100,111]. The fat deposit in the chest
wall can modify the respiratory mechanisms and affects
gas exchange, worsening ventilation-perfusion matching
particularly in the supine position. Breathing at low
volumes not only results in breathing in a less compliant
portion of the pressure-volume curve with increased effort










PaO2 (awake) Normal or ↓
HCO3- Normal
Respiratory drive ↑↑
HVR Normal to ↑
HCVR Normal to ↑
P 0.1 ↑
MVV ↓
Pimax Normal or ↓
Work of breathing Sitting – normal t
Supine - ↑↑
Sleep - sitting - ↑
Supine - ↑↑
Upper airway resistance Sitting - norma
Supine - ↑
FRC: functional residual capacity, ERV: expiratory reserve volume; TLC: total lung cap
response; MVV: maximal minute ventilation. ↑: mild increase; ↑↑: moderate increasein tidal flow limitation, small tidal volumes and higher
respiratory rate compared to non-obese [112-114]. This
strategy is thought to optimize the oxygen cost of breath-
ing, but also increases dead space. PEEPi imposes an
additional threshold load on inspiratory muscles before
any inspiratory flow is generated. All together, this can
lead to a threefold increase in the work of breathing,
both in the sitting and supine positions [110,115]. OHSristics between morbid obesity without or















o ↑ Sitting - ↑↑
Supine - ↑↑↑
↑
l Sitting - ↑
Supine - ↑↑↑
acity; HVR: hypoxic ventilatory response; HCVR: hypercapnic ventilatory
; ↑↑↑: strong increase; ↓: mild decrease; ↓↓: moderate decrease.
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breathing (15% compared to 3% in nonobese subjects)
as well, which may result in a relative state of respira-
tory muscle fatigue [110,116,117]. Maximal voluntary
ventilation, a measure of ventilatory endurance, is reduced
in simple obesity and further reduced in OHS [4,110].
Patients with OHS also have a higher upper airway
resistance both in the sitting and supine position, when
compared to patients with moderate-to-severe OSA with
similar degrees of obesity and control subjects [51,118].
Similarities and differences in lung function characteristics
between morbid obesity without or with hypoventilation
are summarized in Table 1.
The role of diaphragmatic weakness in the pathogenesis
of this disorder remains uncertain, because patients with
OHS can generate similar transdiaphragmatic pressures
at any level of diaphragmatic activation compared to
eucapnic obese subjects [116,117]. Pankow et al. have
shown that non-invasive positive-pressure ventilation
unloads the inspiratory muscles in patients with OHS
[113]. These results emphasize the role of respiratory
muscle fatigue in OHS [118,119]. Values of maximum
inspiratory and expiratory pressures less than 70%
predicted should prompt the clinician to consider OHS
rather than simple OSA [100].
It could be speculated that respiratory muscle per-
formance may be affected by the biochemical disturbance
associated with hypoventilation (acidosis,hypoxemia,
hypercapnia, inflammation). Hypercapnia is known to
have deleterious effects on diaphragmatic function.
Recently, Monneret et al. reported that insulin growth
factor I (IGF-I) levels were inversely related to the vital
capacity in OHS, an indirect marker of diaphragmatic
strength. This indicates that IGF-I plays a role in the
mechanical capacity of the diaphragm [120,121]. More-
over, the relationship between increased triglycerides
and low IGF-I may represent one of the mechanisms
involved in the OHS increased cardio-vascular risk, given
that IGF-I is a well-established vascular protective factor.
Another possible mechanism may be related to the
metabolic syndrome and the low-grade inflammation
associated with excess visceral and intrathoracic adiposity.
Lin et al. have shown that metabolic syndrome was
associated with a higher risk of restrictive lung impairment
after adjustment for confounders (age, gender, BMI,
physical activity, alcohol consumption) [119].
Thus, it is difficult to determine whether respiratory
muscle fatigue is a cause or effect of OHS [122]. Whether
a primary myopathic process also exists is currently
unknown, as detailed muscle structural analysis has not
been performed in subjects with OHS. In addition, the
higher degree of central fat deposition compared with
eucapnic obese patients results in a more pronounced
cephalic displacement of the diaphragm. Compressionof dependent zones and closure of small airways,which
worsens in the supine position [123], and reduction of
lung volumes and altering gas exchange will result to a
much greater degree than weight deposited peripherally
[103,124]. Improvement in VC and TLC can be achieved
with positive pressure treatment, even without any sig-
nificant change in weight [125]. Such improvements are
explained by improved pulmonary compliance, secondary
to a decrease in the closure of dependent airways and
the opening of microatelectasis.
Therefore, it does not appear that obesity is the only
determinant of hypoventilation, as only a minority of
morbidly obese patients develop chronic hypercapnia
[94,113]. A higher degree of central fat deposition, acting
as a mass load, increased respiratory inertance, changes
in the elastic recoil balance, lung resistance, inspiratory
muscle strength, as well as air trapping, microatelectasis,
V/Q mismatch, tidal flow limitation and increased work of
breathing will finally result in a relative state of respiratory
muscle fatigue. Which of these mechanisms will have
most impact will differ in an individual patient.
Control of breathing and CO2 desensitisation
Obese subjects have increased rates of oxygen consump-
tion (VO2) and carbon dioxide production (VCO2), even
when they are at rest. Thus, obese persons must increase
their minute ventilation to meet the increased oxygen
requirements and maintain adequate alveolar ventilation
[126,127]. The central drive to breathe is significantly
higher in eucapnic subjects with morbid obesity than in
normal-weight individuals. OHS patients fail to augment
drive to compensate for the added load created by excess
weight, permitting a gradual rise in CO2 to take place
[73,116,118]. Central responsiveness to hypercapnia and
hypoxia is blunted in OHS patients compared to normal
weight subjects and eucapnic obese patients with or
without OSA [52,95]. Patients with OHS can achieve
eucapnia during voluntarily hyperventilation, implying
that impairments in respiratory system mechanics alone
do not explain the hypoventilation [86]. In simple obesity,
the mouth occlusion pressure (P0.1 response) is also
higher than seen in nonobese patients [116], but it is
unclear whether this is applicable in OHS as well. The
slope of the hypercapnic ventilatory response is < 1
l/min/mmHg in OHS, between 1.5 and 2.5 l/min/mmHg
in eucapnic obese individuals and 2-3 l/min/mmHg in
healthy subjects [51,128,129]. The decrease in ventilatory
response is attributed to an inadequate increase in tidal
volume as a result of a blunt neural response to hyper-
capnia [73,95], and has been demonstrated to improve
with CPAP or BPAP [130,131] or not [132]. The hypoxic
ventilatory response is also blunted in subjects with OHS.
This abnormality is however not familial and improves
with treatment as well [132,133]. Alterations in ventilatory
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thought [132] and are related to the daytime vigilance
[134]. Individuals with low HCVR exhibit more daytime
sleepiness, which is directly related to a higher percentage
of REM sleep spent in hypoventilation [134]. A lack of
relationship between BMI, HCVR and plasma bicarbonate
was reported by Raurich et al., and with PaCO2 by Kessler
et al., which might indicate on the other hand that obesity
acts as a trigger toward hypoventilation in those patients
who already have physiological abnormalities [54,135].
Gas exchange abnormalities will initially be confined to
REM sleep, but over time buffering of the raised carbon
dioxide produces a secondary depression of respiratory
drive that will further reduce ventilation not only during
sleep but during wakefulness as well [82].
An intriguing component of OHS pathogenesis con-
cerns the metabolic consequences of obesity and its ef-
fect on ventilatory control. Leptin is a protein produced
specifically by the adipose tissue and acts on the central
respiratory centers to stimulate ventilation, whereas leptin
deficiency has been associated with hypoventilation
[136-139]. It has been hypothesized that elevated leptin
levels may be a compensatory mechanism by which
obese subjects remain normocapnic, but resistance to
leptin may develop [140].
A possible mechanism could be central leptin resistance
or reduced cerebrospinal fluid penetration of leptin.
For leptin to affect the respiratory centre and increase
minute ventilation, it has to penetrate the blood-brain
barrier [141-143]. Also alteration at the level of the
central receptor could be hypothesized [144,145]. In
some obese subjects, central leptin resistance may lead
to depressed ventilatory drive and, hence, OHS [146].
Campo et al. reported that higher serum leptin concentra-
tions are also associated with both a reduced respiratory
drive and a reduced response to hypercapnia [147]. Strik-
ingly, leptin levels are a better predictor of hypercapnia
than the degree of adiposity [148]. Yee et al. demonstrated
that regular non-invasive ventilation use reduces leptin in
OHS [87], although evidence is controversial [148].
Treatment of OHS with CPAP usually occurs concomi-
tantly with a leftward shift of hypercapnic or, possibly, with
an increase in the gain of both hypercapnic and hypoxic
responsiveness, although a relationship between improve-
ment in CO2 responsiveness and in PaCO2 may not always
be recognized [130,131,149]. Weight loss by bariatric
surgery improves hypercapnia and hypoxia [150], and
HCVR [151]. This resetting in chemical drive could
indirectly hint to a contribution of OSA to the onset
of OHS.
Last but not least, the sustained hypoxia characteristic
of sleep breathing in OHS may further contribute to the
perpetuation and progression of abnormal breathing
through impairment of the arousal response, furtheradding to the inability of these subjects to unload CO2
following apneic events [152-154].
The above mentioned changes in the respiratory control
system of OHS patients make them more vulnerable to
acute deterioration of their ventilatory systems when
faced with new insults, such as chest infection or mild
worsening of cardiac function. This makes OHS patients
more susceptible to acute ventilatory failure [126,154].
Altogether, the interplay of respiratory control mecha-
nisms and metabolic leptin alterations seems to be of
utmost importance. These lead to inability to increase
central respiratory drive, consequent CO2 accumulation,
blunting of chemoreceptors and finally CO2 retention
during the daytime. The precise mechanism on how
leptin exerts its central effects is still questioned, but
could be linked with leptin receptor gene variations
and altered signal transduction [155-157].Obstructive sleep apnea and upper airway patency
There is abundant evidence that OHS is tightly linked
with sleep-disordered breathing, most commonly OSA
[99]. Approximately 90% of OHS patients have underlying
OSA [4].
Excessive fat deposition induces an enlargement of soft
tissues surrounding the upper airway, compromising the
pharyngeal airspace, and therefore predisposing the airway
to closure during sleep [126]. Moreover, the reduced lung
volumes reduced the inspiratory-related caudal tracheal
traction that stabilizes upper airway structures [158].
Also fluid shifts from the legs to the neck during sleep
contribute to the pathogenesis of OSA [44]. OSA could
predispose to daytime hypercapnia by causing nocturnal
hypoxemia [68] and sleep fragmentation [159] that, in
turn, impair mass load compensation thereby predisposing
obese patients to blunting of the respiratory drive and
hypercapnia [4,72]. This was supported by studies that
have correlated nocturnal desaturation (but not AHI)
with hypercapnia [160]. Loss of the so-called normal CO2
response to apnea that protects against the development
of hypercapnia by stimulating respiratory compensation
for each apnea during the interapnea period is thought to
predispose to daytime hypercapnia in patients with OSA
[59,161]. Patients with these concurrent syndromes
may be caught in a “vicious circle”, which may lead to
more severe exposure to hypoxemia and hypercapnia
and further attenuation of the ventilatory response [4].
However, there are some conflicting data regarding the
impact of OSA. In a series of 219 patients with OHS, the
only variables that correlated with a decreased HCVR
were high daytime PaCO2 and older age in men, whereas
in women an elevated BMI correlated with an increase in
HCVR [162]. A relationship between HCVR and OSA
could not be demonstrated, while another study showed
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hypercapnia [163].
The remaining 10% of patients with OHS have an
apnea-hypopnea index less than 5 [164,165]. The sleep-
disordered breathing in this subset of patients has been
labelled as sleep hypoventilation and is defined as an
increase in PaCO2 during sleep by 10 mmHg above
wakefulness or significant oxygen desaturation that is
not explained by obstructive apneas or hypopneas
[164]. It was shown that a significant proportion of
these patients diagnosed initially with isolated sleep
hypoventilation will later exhibit OSA if withdrawn
from non-invasive ventilation [166]. The development
of awake hypercapnia has been shown to correlate
strongly with the proportion of sleep time spent less
than 90% SaO2 [97]. However, it is probably not the
hypoxemia, but the underlying hypoventilation that
leads or aggravates hypercapnia with a spill over during
the daytime when desensitisation occurs. On the other
hand, again, hypoxia could interfere with the synthesis
of a number of neurotransmitters involved in central
respiratory control, including γ-aminobutyric acid, do-
pamine and adenosine, and hence with worsening of
sleep hypoventilation [167]. Summarized, upper airway
patency is often impaired in obesity due to excessive fat
deposition, reduced caudal tracheal traction and fluid
shifts, promoting the development of OSA. OSA in itself
can be associated with hypercapnia by causing hypoxemia,
sleep fragmentation and depressed CO2 drive.
Model combining sleep-disordered breathing, central
respiratory drive and renal buffering
The role of OSA in the pathogenesis of hypoventilation
has been established by the resolution of hypercapnia
in the majority of patients with OHS treated with CPAP
or BPAP without any significant change in BMI. There
is pathophysiologic basis behind how severe OSA, as
measured by AHI, could lead to hypercapnia [66,168,169].
In patients with OSA, the minute ventilation during
sleep does not decrease due to the large increase in the
minute ventilation between the obstructive respiratory
events. Obstructive apneas can, however, lead to acute
hypercapnia if the duration of the inter-event hyper-
ventilation is inadequate to eliminate the accumulated
CO2 [169]. In cases of very severe OSA, there is not much
time left to increase the minute ventilation between
the obstructive events and to off-load CO2, leading to
significant nocturnal hypercapnia. This acute hyper-
capnia causes a small increase in serum bicarbonate
level that is not corrected before the next sleep period
if the time constant of bicarbonate excretion is longer
than that of CO2. Because the bicarbonate in the
serum (and brain tissue) rises during the chronic,
compensated respiratory acidosis, the baseline pH ofthe cerebrospinal fluid is actually well defended, so the
pH and the stimulus for the brainstem chemoreceptors
are not much changed in the steady state. However,
should the CO2 level rise further, elevated bicarbonate
level will blunt the ventilatory response to CO2 by
reducing the change in pH associated with the change
in CO2, and the chemosensory stimulus will be less for
any given change in the level of CO2 [170]. This would
ultimately result in a higher wake CO2 level [113,168].
In a recent study it was confirmed that patients with
higher bicarbonate concentration had a more blunted
CO2 response [135]. The development of decreased central
respiratory drive and/or the greater ventilatory limitations
imposed by more extreme central obesity may initiate
the acute failure to compensate for OSA, but only if the
renal compensatory mechanism is impaired [100,171]. In
other words, whether or not daytime chronic hypercapnia
develops depends on the individual’s ability to unload
both CO2 and bicarbonate during the waking period
[168]. Thus, deficient renal bicarbonate excretion seems
to play a critical pathophysiologic role, leading to a cu-
mulative effect over subsequent periods of sleep, which
eventually results in a self-perpetuating state of chronic
hypercapnia. Hence, the presence of obstructive apneas
can trigger a vicious circle of acute hypercapnia, blunting
the ventilatory response to CO2, but only if the renal
buffering capacity is impaired. Concommittant presence
of morbid obesity and airway obstruction could also lead
more easily to limitation of the interapneic ventilation.
This could represent a common mechanism by which
COPD and obesity could predispose to the development
of hypercapnia in OSA.
Neurohormonal changes
Besides leptin, adipose tissue is able to express numer-
ous other adipokines, that are involved in energy
homeostasis, as well as in vascular and endothelial
physiology. These adipokines are thought to be the
mediators of endothelial injury and atherosclerosis [172].
Although most adipokines promote insulin resistance
and endothelial dysfunction, adiponectin (with insulin
sensitizing and antiatherogenic effects) protects against
these disorders. Adiponectin levels are decreased in
obesity [173] and inversely correlated with cardiovascular
morbidity. With both systemic hypoxia and tissue
ischemia, adipokine levels are altered, with downregu-
lation of adipokine expression and upregulation of leptin
through HIF-1α activation [174,175]. Recently, Borel et al.
reported that OHS is associated with a specific increase
in the pro-atherosclerotic RANTES chemokine, a decrease
in the anti-inflammatory adipokine adiponectin and
impaired endothelial function. These three conditions
are known to be strongly associated with an increased
cardiovascular risk [176]. Based on these findings, OHS
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inflammation and aggravated endothelial dysfunction.
Moreover, they proposed to distinguish subclasses of
inflammation among obese populations reflecting different
risks and allowing tailoring specific anti-inflammatory
treatments. Hence, the role of nocturnal hypoxia resulting
from nocturnal hypoventilation and recurrent apneas,
when present, may be critical. It might explain, at least
partly, the excess of morbidity and mortality occurring
in OHS [176]. Moreover, non invasive ventilation, the
current first line therapy of OHS, should now be evaluated,
in randomized controlled trials, not ony regarding its
effects on PaCO2, sleep and quality of life, but also for
its cardiovascular and metabolic impact [176]. These data
illustrate the complex picture of OHS, and its cardiovascu-
lar consequences. However, adipokines other than leptin
do not seem to be involved in the pathogenesis of OHS.
Differences and similarities between overlap
syndrome and obesity hypoventilation
Although overlap syndrome and OHS are very different
conditions, they share some pathogenetic and clinical
aspects [177], and represent substantial morbidity and
mortality (Table 2). On the one hand, from the patho-
physiologic point of view, the presence of COPD does not
favour the occurrence of OSA and vice versa, and hence
the occurrence of overlap syndrome is by coincidence
[24]. In OHS, on the other hand, there is abundant
evidence that it is tightly linked with OSA [4,100], and
only a minority has nonobstructive sleep-disordered
breathing [66,100]. However, overlap patients haveTable 2 Similarities and differences between overlap syndrom
Overlap
Coexistent OSA No causal relat
Hypoventilation (PaCO2 ≥ 45 mmHg) Occasiona
Obesity (BMI ≥ 30 kg/m2) Often (but not o
Coexistent COPD Always (by def
Coexistent restrictive pulmonary disease Occasionally mixe
FRC Decrease
Chemosensitivity (HCVR) Normal, enhanced o
Leptine resistance Present
Hypoxemia pattern Intermittent (intermittent and c
Level of hypoxemia Absent to very severe
Prevalence in general population 1-4%
Prevalence in OSA 10%
Pulmonary hypertension + to ++
Health care consumption Increased
Mortality 80% in 12 y
90% in 8 years
+: mild increase; ++ moderate increase; +++severe increase.important sleep-related oxygen desaturation and represent
a high risk of developing hypercapnia and pulmonary
hypertension, even in the presence of mild to moderate
bronchial obstruction. OHS patients will, by definition,
present always with respiratory insufficiency, and are
therefore more often at risk for morbidity and mortality
than the overlap population. Both disorders share complex
interactions, among which are increased work of breath-
ing related to (central) obesity, alterations of ventilatory
drive, various associated sleep breathing disorders and
neurohormonal changes such as leptin resistance. How-
ever, those with overlap syndrome do not necessarily
present with obesity, and the ventilatory drive can be
normal, enhanced or reduced [50,51] and the presence
of hypoventilation is optional.
The interindividual differences are intricate, reflecting
phenotypic complexity and admixture with various other
respiratory diatheses (e.g. smoking). In OHS, pathogenetic
factors like obesity related decrease in chest wall com-
pliance do not in general appear to be sufficient to
cause OHS as they are present in many non-hypercapnic
obese individuals. However, when minute ventilation falls
below a range necessary to compensate for the metabolic
demands, hypercapnia will result.
These mechanisms can play a role in some obese
patients with overlap syndrome as well, but hypo-
ventilation will finally emerge when compensatory
mechanisms of CO2 homeostasis fail or become over-
whelmed [67,178,179]. Both syndromes share a high
prevalence, namely 10 to 20% for OHS in patients with
OSA [4,96,100], while COPD is reported in about 10%e and obesity hypoventilation
Obesity hypoventilation syndrome
ionship Causal relationship in 90% of the cases
lly Always (by definition)
bligatory) Always (by definition)
inition) Never (exclusion by definition)




hronic in severe cases) Intermittent and chronic (90%), or chronic (10%)





ears 23% in 1.5 years
in LTOT
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higher figures [20-24]. The prevalence of overlap and
OHS in the general population is estimated to be 1%
and 0.37% respectively [20-23,96-98]. Both overlap and
OHS patients can present with the typical symptoms of
OSA, but depending on the complexity of the syndromes,
some particularities can be observed. Those with OHS
can have characteristic symptoms, on the one hand, due
to elevated PaCO2, and consist of cognitive impairment,
daytime hypersomnolence and morning headache. Chronic
hypoxemia during wakefulness, on the other hand, leads to
signs of cor pulmonale, pulmonary hypertension, polycy-
themia, and respiratory failure. Sleep-disordered breathing
is most often present with symptoms of loud snoring,
fragmented sleep, gasping, nocturia, fatigue and non-
restorative sleep. The clinical manifestations of OHS
depend on the degree of obesity, the presence of
comorbidity like OSA and, of course, on the degree of
hypoventilation. Overlap patients can also present these
symptoms, depending on the relative contribution of
the two components to the syndrome, and the eventual
development of respiratory failure. In OSA patients
with advanced stage COPD, dyspnea, orthopnea and
peripheral edema are also common and can be the
dominant symptoms, while only a minority of overlap
patients will develop respiratory insufficiency. Therefore,
it can be estimated that these symptoms will be less
common than in OHS. In both disorders, also a high
prevalence of pulmonary hypertension was reported.
Closely related to the most often more severe hypercapnia
and hypoxemia during the daytime found in OHS, these
patients present with a higher prevalence of pulmonary
hypertension [88,109,135,180]. However, thresholds for
hypercapnia/hypoxemia severity and duration necessary
to give rise to sleep-related symptoms or cardiovascular
complications, such as pulmonary hypertension, in
individual OHS patients, are unknown. The change in
evening to morning PaCO2 has been shown to be
highly correlated with severity of sleep hypoventilation,
and could be used as a marker [181]. In patients with
overlap syndrome, also no cut-off values have been
defined that warrant treatment, but an AHI ≥ 15 has
been shown in isolated OSA to be clinically relevant
[182]. This criterion could be applied in both syndromes
[183]. Overlap syndrome as well as OHS also share a
higher morbidity [7,17,54,76,78-80,135,170,181,182] and
mortality [16,26,96,184,185], decreased quality of life
[58,186], and an increased use of health care resources
[187,188]. OHS is associated with chronic heart failure,
angina, arterial hypertension, cor pulmonale and endothe-
lial dysfunction, while overlap syndrome is associated
with arterial hypertension, new onset atrial fibrillation
and cardiovascular remodelling. Patients with OHS
tend to use more antihypertensive drugs, have higherinsulin resistance, and are more likely to be treated with
antidiabetic agents [16,135,164,187]. Overlap patients
also more often present with COPD exacerbations than
simple COPD patients (relative risk of 1.70) [16] and
show a trend to less prednisolone use after treatment
[28]. OHS patients who refused treatment with non-
invasive ventilation, had a mortality rate of 46% over an
average follow-up period of 50 months [88]. In overlap,
reduced survival was reported in those refusing CPAP
therapy (relative risk of 1.79) [15,184]. Chronic daytime
hypercapnia would emerge if both the acute ventilatory
compensation for transient nocturnal hypercapnia is
compromised, as well as the bicarbonate excretion, as
might be seen under condition of hypoxia (f.i. chest
infection), diuretic therapy, or heart failure [170,178].
This makes both patient categories more susceptible to
acute ventilatory failure [126]. Despite this, the diagnosis
of overlap syndrome and of OHS appears to be often
overlooked, especially in a clinical setting when dealing
with the other illnesses of these patients [189]. The evi-
dence however supports that recognition and treatment
of both diseases is imperative.Conclusion
Overlap syndrome and OHS are not rare conditions,
due to the high prevalence of COPD, obesity and OSA.
They are both serious medical disorders associated with
significant morbidity and mortality. Its diagnosis can
have a significant impact on an individual subject and
on the health care system as a whole. Both conditions
present unique characteristics which set them apart from
either COPD, obesity or OSA. They share some common
pathways, and hypercapnia will develop when the normal
compensatory mechanisms that should normally operate
to maintain ventilation despite respiratory system abnor-
malities are impaired. Obesity is generally believed to be
the major etiologic factor responsible for both syndromes
in the majority of the patients. The interaction between
the components of these two diseases is not completely
disentangled, and may reflect phenotypic complexity and
admixture with various other respiratory diatheses. Factors
that compromise the acute ventilatory compensation
for the transient sleep hypercapnia, altered bicarbonate
excretion and respiratory mechanics finally determine
the development or deterioration of hypoventilation.
Recognition of sleep-related disturbances and a better
understanding of their interactions in subjects with COPD
and in subjects with obesity will allow to optimize
management of these patients and their quality of life.Competing interest
The authors declare that they have no competing interests.
Verbraecken and McNicholas Respiratory Research 2013, 14:132 Page 14 of 17
http://respiratory-research.com/content/14/1/132Authors’ contributions
JV and WM conceived of the study, and participated in its design and
coordination and drafted the manuscript. Both authors read and approved
the final manuscript.
Author details
1Department of Pulmonary Medicine and Multidisciplinary Sleep Disorders
Centre, Antwerp University Hospital and University of Antwerp, Wilrijkstraat
10, Edegem 2650, Belgium. 2Pulmonary and Sleep Disorders Unit,
St. Vincent’s University Hospital, Dublin, Ireland. 3Conway Institute of
Biomolecular and Biomedical Research, University College Dublin,
Dublin, Ireland.
Received: 14 June 2013 Accepted: 15 November 2013
Published: 20 November 2013
References
1. Verbraecken J, De Backer W: Upper airway mechanics. Respiration 2009,
78:121–133.
2. Zamarron C, Garcia Paz V, Morete E, del Campo MF: Association of chronic
obstructive pulmonary disease and obstructive sleep apnea
consequences. Int J COPD 2008, 3(4):671–682.
3. Weitzenblum E, Chaouat A, Kessler R, Canuet M: Overlap syndrome.
Obstructive sleep apnea in patients with chronic obstructive pulmonary
disease. Proc Am Thorac Soc 2008, 5:237–241.
4. Olson AL, Zwillich C: The obesity hypoventilation syndrome. Am J Med
2005, 118:948–956.
5. Berger KI, Ayappa I, Chatr-Amontri B, Marfatia A, Sorkin IB, Rapoport DM,
Goldring RM: Obesity hypoventilation syndrome as a spectrum of
respiratory disturbances during sleep. Chest 2001, 120:1231–1238.
6. de Llano Pérez LA, Golpe R, Piquer MO, Racamonde AV, Caruncho MV,
López MJ, Fariñas MC: Clinical heterogeneity among patients with obesity
hypoventilation syndrome: therapeutic implications. Respiration 2008,
75:34–39.
7. Borel JC, Borel AL, Monneret D, Tamisier R, Levy P, Pepin JL: Obesity
hypoventilation syndrome: from sleep-disordered breathing to systemic
comorbidities and the need to offer combined treatment strategies.
Respirology 2012, 17:601–610.
8. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of
sleep-disordered breathing among middle-aged adults. N Engl J Med
1993, 323:1230–1235.
9. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V,
Buist S: Chronic obstructive pulmonary disease: current burden and
future projections. Eur Respir J 2006, 27:397–412.
10. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ,
Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R:
Epidemiology and costs of chronic obstructive pulmonary disease.
Eur Respir J 2006, 27:188–207.
11. Gordon-Larsen P, Adair LS, Nelson MC, Popkin BM: Five-year obesity
incidence in the transition period between adolescence and adulthood:
the national longitudinal study of adolescent health. Am J Clin Nutr 2004,
80:569–575.
12. Ogar CL, Fryar CD, Carroll MD, Flegal KM: Mean body weight, height and
BMI, United States 1960-2002. Adv Data 2004, 347:1–17.
13. Davies RM, Novotny TE: The epidemiology of cigarette smoking and its
impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989,
140:S82–S84.
14. Hiestand D, Philips B: The overlap syndrome: chronic obstructive pulmonary
disease and obstructive sleep apnea. Crit Care Clin 2008, 24:551–563.
15. Marin JM, Carrizo SJ, Vicneti E, Agusti AG: Long-term cardiovascular
outcomes in men with obstructive sleep apnoea-hypopnoea with or
without treatment with continuous positive airway pressure: an
observational study. Lancet 2005, 365:1046–1053.
16. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR: Outcomes in patients
with chronic obstructive pulmonary disease and obstructive sleep apnea:
the overlap syndrome. Am J Respir Crit Care Med 2010, 182(3):325–331.
17. Borel JC, Burel B, Tamisier R, Dias-Domingos S, Bauet JP, Levy P, Pepin JL:
Comorbidities and mortality in hypercapnic obese under domiciliary
non-invasive ventilation. Plose One 2013, 8(1):e52006. 1-8.
18. American Academy of Sleep Medicine Task Force: Sleep-related breathing
disorders in adults: recommendations for syndrome definition andmeasurement techniques in clinical research. The report of an American
academy of sleep medicine task force. Sleep 1999, 22:667–689.
19. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL,
Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL,
Tangredi MM: Rules for scoring respiratory events in sleep: update of the
2007 AASM manual for the scoring of sleep and associated events.
J Clin Sleep Med 2012, 8(5):597–619.
20. Guilleminault C, Cummiskey J, Motta J: Chronic obstructive airflow disease
and sleep studies. Am Rev Respir Dis 1980, 122:397–406.
21. Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R:
Association of chronic obstructive pulmonary disease and sleep apnea
syndrome. Am Rev Respir Dis 1995, 151:82–86.
22. Bradley TD, Rutherford A, Grossmann RF, Lue F, Zamel N, Moldosfsky H,
Phillipson EA: Role of daytime hypoxemia in the pathogenesis of right
heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis
1985, 131:835–839.
23. Bradley TD, Rutherford A, Lue F, Moldofsky H, Grossmann RF, Zamel N,
Phillipson EA: Role of diffuse airway obstruction in the hypercapnia of
obstructive apnea. Am Rev Respir Dis 1986, 134:920–924.
24. Sanders MH, Newman AB, Haggerty CL, Redline S, Lebowitz M, Samet J,
O'Connor GT, Punjabi NM, Shahar E: Sleep heart health study: sleep and
sleep-disordered breathing in adults with predominantly mild obstructive
airway disease. Am J Respir Crit Care Med 2003, 167:7–14.
25. Lundbäck B, Lindberg A, Lindström M, Rönmark E, Jonsson AC, Jönsson E,
Larsson LG, Andersson S, Sandström T, Larsson K: Obstructive lung disease
in Nothern Sweden studies: not 15 but 50% of smokers develop COPD?
Report from the obstructive lung disease in Nothern Sweden studies.
Respir Med 2003, 97(2):115–122.
26. McNicholas WT, Verbraecken J, Marin J: Sleep disorders in COPD: the
forgotten dimension. Eur Respir Rev 2013, 22:365–375.
27. Resta O, Barbaro MPF, Bonfitto P, Talamo S, Mastrosimone V, Stefano A,
Giliberti T: Hypercapnia in obstructive sleep apnoea syndrome. Neth J
Med 2000, 56:215–222.
28. O’Brien A, Whitman K: Lack of benefit of continuous positive airway pressure
on lung function in patients with overlap syndrome. Lung 2005, 183:389–404.
29. Engelen MP, Schols AM, Does JD, Wouters EF: Skeletal muscle weakness is
associated with wasting of extremity fat-free mass but not with airflow
obstruction in patients with chronic obstructive pulmonary disease.
Am J Clin Nutr 2000, 71:733–738.
30. McNicholas WT: Chronic obstructive pulmonary disease and obstructive
sleep apnea. Overlaps in pathophysiology, systemic inflammation, and
cardiovascular disease. Am J Respir Crit Care Med 2009, 180:692–700.
31. Young T, Peppard PR, Gottlieb DJ: Epidemiology of obstructive sleep
apnea: a population health perspective. Am J Respir Crit Care Med 2002,
165:1217–1239.
32. Wetter DW, Young TB, Bidwell TR, Badr MS, Palta M: Smoking as a risk factor
for sleep-disordered breathing. Arch Intern Med 1994, 154:2219–2224.
33. Kim KS, Kim JH, Park SY, Won HR, Lee HJ, Yang HS, Kim HJ: Smoking
induces oropharyngeal narrowing and increases the severity of
obstructive sleep apnea syndrome. J Clin Sleep Med 2012, 8(4):367–374.
34. McNicholas WT: Impact of sleep in COPD. Chest 2000, 117:48S–53S.
35. Stege G, Vos PE, van den Elshout FJJ, Dekhuijzen PNR, van de Ven MJT,
Heijdra YF: Sleep, hypnotics and chronic obstructive pulmonary disease.
Respir Med 2008, 102(6):801–814.
36. Ballard RD, Clover CW, Suh BY: Influence of sleep on respiratory function
in emphysema. Am J Respir Crit Care Med 1995, 151:945–951.
37. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S: Effect of
tiotropium bromide on circadian variation in airflow limitation in chronic
obstructive pulmonary disease. Thorax 2003, 58(10):855–860.
38. Dawkins KD, Muers MF: Diurnal variation in airflow obstruction in chronic
bronchitis. Thorax 1981, 36:618–621.
39. Postma DS, Koeter GH, van de Mark TW, Reig RP, Sluiter HJ: The effects of
oral slow-release terbutaline on the circadian variation in spirometry and
arterial blood gas levels in patients with chronic airflow obstruction.
Chest 1985, 87(5):653–657.
40. Koo KW, Sax DS, Snider GL: Arterial blood gases and pH during sleep in
chronic obstructive pulmonary disease. Am J Med 1975, 58(5):663–670.
41. Johnson MW, Remmers JE: Accessory muscle activity during sleep in
chronic obstructive pulmonary disease. J Appl Physiol 1984, 57:1011–1017.
42. Ezzie ME, Parsons JP, Mastronarde JG: Sleep and obstructive lung diseases.
Sleep Med Clin 2008, 3:505–515.
Verbraecken and McNicholas Respiratory Research 2013, 14:132 Page 15 of 17
http://respiratory-research.com/content/14/1/13243. Hudgel DW, Devadatta P: Decrease in functional residual capacity during
sleep in normal humans. J Appl Physiol 1984, 57:1319–1322.
44. Redolfi S, Yumino D, Ruttanaumpawan P, Yau B, Su MC, Lam J, Bradley TD:
Relationship between overnight rostral fluid shift and obstructive sleep
apnea in nonobese men. Am J Respir Crit Care Med 2009, 179:241–246.
45. Shujaat A, Minkin R, Eden E: Pulmonary hypertension and chronic cor
pulmonale in COPD. Int J Chron Obstruct Pulmon Dis 2007, 2(3):273–282.
46. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL: Pulmonary
hemodynamics in patients with chronic obstructive pulmonary disease
before and during an episode of peripheral edema. Chest 1994,
105:1377–1382.
47. De Leeuw PW, Dees A: Fluid homeostasis in chronic obstructive lung
disease. Eur Respir J 2003, 22(Suppl 46):33s–40s.
48. Novali M, Piana GL, Montemurro LT, Bertella E, Redolfi S, Corda L, Tantucci C:
Predictive factors of sleep oxygen desaturation in COPD patients without
daytime respiratory failure and OSAH [abstract]. Am J Respir Crit Care Med
2008, 177:A935.
49. Degache F, Sforza E, Dauphinot V, Celle S, Garcin A, Collet P, Pichot V,
Barthélémy JC, Roche F, PROOF Study Group: Relation of central fat mass
to obstructive sleep apnea in the elderly. Sleep 2013, 36(4):501–507.
50. Radwan L, Maszczyk Z, Koziorowski A, Koziej M, Cieslicki J, Sliwinski P,
Zielinski J: Control of breathing in obstructive sleep apnoea and in
patients with the overlap syndrome. Eur Respir J 1995, 8:542–545.
51. Verbraecken J, De Backer W, Willemen M, De Cock W, Wittesaele W,
Van de Heyning P: Chronic CO2 drive in patients with obstructive sleep
apnea and effect of CPAP. Respir Physiol 1995, 101:279–287.
52. Zwillich CW, Sutton FD, Pierson DJ, Greagh EM, Weil JV: Decreased hypoxic
ventilatory drive in the obesity hypoventilation syndrome. Am J Med
1975, 59:343–348.
53. Erbland ML, Ebert RV, Snow SL: Interaction of hypoxia and hypercapnia on
respiratory drive in patients with COPD. Chest 1990, 97:1289–1294.
54. Kessler R, Chaouat A, Schinkewitch P, Faller M, Casel S, Krieger J,
Weitzenblum E: The obesity-hypoventilation syndrome revisited: a pro-
spective study of 34 consecutive cases. Chest 2001, 120:369–376.
55. Soriano JB, Yáñez A, Renom F, de la Peña M, Gómez A, Duro R, Uréndez A,
Román M: Set-up and pilot of a population cohort for the study of the
natural history of COPD and OSA: the PULSAIB study. Prim Care Respir J
2010, 19(2):140–147.
56. Kwon JS, Wolf LF, Lu B, Kalhan R: Hyperinflation is associated with lower
sleep efficiency in COPD with co-existent obstructive sleep apnea.
J Chron Obstr Pulm Dis 2009, 6:441–445.
57. Tsai SC, Lee-Chiong T: Lung hyperinflation and sleep quality in the overlap
syndrome. J Chron Obstr Pulm Dis 2009, 6:419–420.
58. Mermigkis C, Kopanakis A, Fodvary-Schaefer N, Golish J, Polychronopoulos V,
Schiza S, Amfilochiou A, Siafakas N, Bouros D: Health-related quality of life in
patients with obstructive sleep apnea and chronic obstructive pulmonary
disease (overlap syndrome). Int J Clin Pract 2007, 61:207–211.
59. Berger KI, Ayappa I, Sorkin IB, Norman RG, Rapoport DM, Goldring RM:
Postevent ventilation as a function of CO2 load during respiratory events
in obstructive sleep apnea. J Appl Physiol 2002, 93:917–924.
60. Series F, Cormier Y, La Forge J: Role of lung volumes in sleep apnoea
related oxygen desaturation. Eur Respir J 1989, 2:26–30.
61. Series F, Marc I: Influence of lung volume dependence of upper airway
resistance during continuous negative airway pressure. J Appl Physiol
1994, 77:840–844.
62. Heinzer RC, Stanchina ML, Malhotra A, Jordan AS, Patel SR, Lo YL, Wellman
A, Schory K, Dover L, White DP: Effect of increased lung volume on sleep
disordered breathing in sleep apnoea patients. Thorax 2006, 61:435–439.
63. Bednarek M, Plywaczewski R, Jonczak L, Zielinski J: There is no
relationshiop between chronic obstructive pulmonary disease and
obstructive sleep apnea syndrome: a population study. Respiration 2005,
72:142–149.
64. Douglas NJ, White DP, Pickett CK, Weil JV, Zwillich CW: Respiration during
sleep in normal man. Thorax 1982, 37:840–844.
65. Douglas J, White DP, Weil JV, Pickett CK, Zwillich CW: Hypercapnic ventilatory
response in sleeping adults. Am Rev Respir Dis 1982, 126:758–762.
66. Berger KI, Ayappa I, Sorkin IB, Norman RG, Rapoport DM, Goldring RM: CO
(2) homeostasis during periodic breathing in obstructive sleep apnea.
J Appl Physiol 2000, 88(1):257–264.
67. Berger KI, Norman RG, Ayappa I, Oppenheimer BW, Rapoport DM, Goldring
RM: Potential mechanism for transition between acute hypercapniaduring sleep to chronic hypercapnia during wakefulness in obstructive
sleep apnea. Adv Exp Med Biol 2008, 605:431–436.
68. Weil JV, Byrne-Quin IE, Sodal IE, Filley GF, Grover RF: Acquired attenuation
of chemoreceptor function in chronically hypoxic man at high altitude.
J Clin Invest 1971, 50:186–195.
69. Gold AR, Schwartz AR, Bleecker ER, Smith PL: The effect of chronic
nocturnal oxygen administration upon sleep apnea. Am Rev Respir Dis
1986, 134:925–929.
70. Leech JA, Onal E, Lopata M: Nasal CPAP continues to improve
sleep-disordered breathing and daytime oxygenation over long-term
follow-up of occlusive sleep apnea syndrome. Chest 1992, 102:1651–1655.
71. Chaouat A, Weitzenblum E, Kessler R, Charpentier C, Ehrhart M, Levi-Valensi P,
Zielinski J, Delaunois L, Cornudella R, Moutinho dos Santos J: Sleep-related O2
desaturation and daytime pulmonary haemodynamics in COPD patients
with mild hypoxaemia. Eur Respir J 1997, 10:1730–1735.
72. Garay SM, Rapoport D, Sorkin B, Epstein H, Feinberg I, Goldring RM:
Regulation of ventilation in the obstructive sleep apnea syndrome.
Am Rev Respir Dis 1981, 124:451–457.
73. Lopata M, Onal E: Mass loading, sleep apnea, and the pathogenesis of
obesity hypoventilation. Am Rev Respir Dis 1982, 126:640–645.
74. Guilleminault C, Cummiskey J: Progressive improvement in apnea index
and ventilatory response to CO2 after tracheostomy in obstructive sleep
apnea. Am Rev Respir Dis 1982, 126:14–20.
75. Mountain R, Zwillich CW, Weil JV: Hypoventilation in obstructive lung
disease. The role of familial factors. N Engl J Med 1978, 298:521–525.
76. Hawrylkiewicz I, Sliwinski P, Gorecka D, Pływaczewski R, Zieliński J:
Pulmonary haemodynamics in patients with OSAS or an overlap
syndrome. Monaldi Arch Chest Dis 2004, 61:148–152.
77. Chaouat A, Naeije R, Weitzenblum E: Pulmonary hypertension in COPD.
Eur Respir J 2008, 32(5):1371–1385.
78. Shiina K, Tomiyama H, Takata Y, Yoshida M, Kato K, Nishihata Y, Matsumoto C,
Odaira M, Saruhara H, Hashimura Y, Usui Y, Yamashina A: Overlap syndrome:
additive effects of COPD on the cardiovascular damages in patients with
OSA. Respir Med 2012, 106(9):1335–1341.
79. Sharma B, Neilan TG, Kwong RY, Mandry D, Owens RL, McSharry D, Bakker JP,
Malhotra A: Evaluation of right ventricular remodeling using cardiac
magnetic resonance imaging in co-existent chronic obstructive pulmonary
disease and obstructive sleep apnea. COPD 2013, 10(1):4–10.
80. Ganga HV, Nair SU, Puppala VK, Miller WL: Risk of new-onset atrial fibrillation
in elderly patients with the overlap syndrome: a retrospective cohort study.
J Geriatr Cardiol 2013, 10(2):129–134.
81. Piper AJ, Grunstein RR: Obesity hypoventilation syndrome. Mechanisms
and management. Am J Respir Crit Care Med 2011, 183:292–298.
82. Piper AJ, Grunstein RR: Big breathing: the complex interaction of obesity,
hypoventilation, weight loss, and respiratory function. J Appl Physiol 2010,
108:199–205.
83. Cherniak NS: What causes hypercapnia? Won’t breathe, can’t breathe or
something in between? Respiration 2008, 75:251–252.
84. Martin TJ, Sanders MH: Chronic alveolar hypoventilation: a review for the
clinician. Sleep 1995, 18:617–634.
85. Teichtahl H: The obesity-hypoventilation syndrome revisited. Chest 2001,
120(2):336–339.
86. Leech J, Önal E, Aronson R, Lopata M: Voluntary hyperventilation in
obesity hypoventilation. Chest 1991, 100:1334–1338.
87. Yee BJ, Cheung J, Philipps P, Banerjee D, Piper AJ: Treatment of obesity
hypoventilation syndrome and serum leptin. Respiration 2006, 73:209–212.
88. de Llano Pérez LA, Golpe R, Ortiz Piquer M, Veres Racamonde A, Vázquez
Caruncho M, Caballero Muinelos O, Alvarez Carro C: Short-term and long-
term effects of nasal intermittent positive pressure ventilation in patients
with obesity-hypoventilation syndrome. Chest 2005, 128:587–594.
89. Selim BJ, Junna MR, Morgenthaler TI: Therapy for sleep hypoventilation and
central apnea syndromes. Curr Treat Options Neurol 2012, 14(5):427–437.
90. Contal O, Adler D, Borel JC, Espa F, Perrig S, Rodenstein D, Pépin JL,
Janssens JP: Impact of different backup respiratory rates on the efficacy
of non-invasive positive pressure ventilation in obesity hypoventilation
syndrome: a randomized trial. Chest 2013, 143(1):37–46.
91. Windisch W, Storre JH: Target volume settings for home mechanical
ventilation: great progress or just a gadget? Thorax 2012, 67(8):663–665.
92. Esquinas AM: Backup respiratory rate during non-invasive positive pressure
ventilation in obesity hypoventilation syndrome: can this difficult puzzle be
resolved? Chest 2013, 143(4):1182–1183.
Verbraecken and McNicholas Respiratory Research 2013, 14:132 Page 16 of 17
http://respiratory-research.com/content/14/1/13293. Laaban JP, Chailleux E: Observatory group of Antadir: daytime
hypercapnia in adults patients with obstructive sleep apnea syndrome
in France, before initiating nocturnal nasal continuous positive airway
pressure therapy. Chest 2005, 127:710–715.
94. Mokhlesi B, Tulaimat A, Faibussowitsch I, Wang Y, Evans A: Obesity
hypoventilation syndrome: prevalence and predictors in patients with
obstructive sleep apnea. Sleep Breath 2007, 11:117–124.
95. Macavei VM, Spurling KJ, Loft J, Makker HK: Diagnostic predictors of
obesity-hypoventilation syndrome in patients suspected of having sleep
disordered breathing. J Clin Sleep Med 2013, 9(9):879–884.
96. Nowbar S, Burkart KM, Gonzales R, Fedorowicz A, Gozansky WS,
Gaudio JC, Taylor MR, Zwillich CW: Obesity-associated hypoventilation
in hospitalized patients: prevalence, effects, and outcome. Am J Med
2004, 116:1–7.
97. Kaw R, Hernandez AV, Walker E, Aboussouan L, Mokhlesi B: Determinants
of hypercapnia in obese patients with obstructive sleep apnea: a
systematic review and metaanalysis of cohort studies. Chest 2009,
136:787–796.
98. Mokhlesi B, Saager L, Kaw RQ: Should we routinely screen for hypercapnia
in sleep apnea patients before elective noncardiac surgery? Cleve Clin J
Med 2010, 77:60–61.
99. Jones RL, Nzekuwu MU: The effects of body mass index on lung volumes.
Chest 2006, 130(3):827–833.
100. Piper AJ: Obesity hypoventilation syndrome – the big and the breathless.
Sleep Med Rev 2011, 15:79–89.
101. Sharp JT, Henry JP, Sweany SK, Meadows WR, Pietras RJ: Total respiratory
system inertance and its gas and tissue components in normal and
obese men. J Clin Invest 1964, 43:503–509.
102. Case KR, Ortiz K, Brown LK: Sleep-related hypoventilation/hypoxemic
syndromes. Chest 2007, 131:1936–1948.
103. Lazarus R, Sparrow D, Weiss ST: Effects of obesity and fat distribution on
ventilatory function: the normative aging study. Chest 1997, 111:891–898.
104. Rubinstein I, Zamel N, DuBarry L, Hoffstein V: Airflow limitation in morbidly
obese, nonsmoking men. Ann Intern Med 1990, 112:828–832.
105. Behazin N, Jones SB, Cohen RI, Loring SH: Respiratory restriction and
elevated pleural and esophageal pressures in morbid obesity. J Appl
Physiol 2010, 108:212–218.
106. Pelosi P, Croci M, Ravagnan I, Vicardi P, Gattinoni L: Total respiratory system,
lung, and chest wall mechanics in sedated-paralyzed post-operative
morbidly obese patients. Chest 1996, 109:144–151.
107. Zerah F, Harf A, Perlemuter L, Lorino H, Lorino AM, Atlan G: Effects of
obesity on respiratory resistance. Chest 1993, 103:1470–1476.
108. Thomas PS, Cowen ERT, Hulands G, Milledge JS: Respiratory function in the
morbidly obese before and after weight loss. Thorax 1989, 4:382–386.
109. Resta O, Foschino-Barbaro MP, Bonfitto P, Talamo S, Legari G, De Pergola G,
Minenna A, Giorgino R: Prevalence and mechanisms of diurnal hypercapnia
in a sample of morbidly obese subjects with obstructive sleep apnoea.
Respir Med 2000, 94:240–246.
110. Sharp JT, Henry JP, Sweany SK, Meadows WR, Pietras RJ: The total work of
breathing in normal and obese men. J Clin Invest 1964, 43:728–739.
111. Pankow W, Podszus T, Gutheil T, Penzel T, Peter J, von Wichert P: Expiratory
flow limitation and intrinsic positive end-expiratory pressure in obesity.
J Appl Physiol 1998, 85:1236–1243.
112. Chlif M, Keochkerian D, Choquet D, Vaidie A, Ahmaidi S: Effects of obesity on
breathing pattern, ventilatory neural drive and mechanics. Respir Physiol
Neurobiol 2009, 168:198–202.
113. Pankow W, Hijjeh N, Schuttler F, Penzel T, Becker HF, Peter JH, von Wichert P:
Influence of noninvasive positive pressure ventilation in obese subjects.
Eur Respir J 1997, 10:2847–2852.
114. Sampson MG, Grassino AE: Load compensation in obese patients during
quiet tidal breathing. J Appl Physiol 1983, 55:1269–1276.
115. Lee MY, Linn CC, Shen SY, Chiu CH, Liaw SF: Work of breathing in eucapnic
and hypercapnic sleep apnea syndrome. Respiration 2009, 77:146–153.
116. Sampson MG, Grassino K: Neuromechanical properties in obese patients
during carbon dioxide rebreathing. Am J Med 1983, 75:81–90.
117. Kress JP, Pohlman AS, Alverdy J, Hall JB: The impact of morbid obesity on
oxygen cost of breathing (Vo2RESP) at rest. Am J Respir Crit Care Med 1999,
160:883–886.
118. Lin CC, Wu KM, Chou CS, Liaw SF: Oral airway resistance during wakefulness
in eucapnic and hypercapnic sleep apnea syndrome. Respir Physiol 2004,
139:215–224.119. Lin WY, Yao CA, Wang HC, Huang KC: Impaired lung function is associated
with obesity and metabolic syndrome in adults. Obesity 2006, 14:1654–1661.
120. Monneret D, Borel JC, Pepin JL, Tamisier R, Arnol N, Levy P, Faure P:
Pleiotropic role of IGF-I in obesity hypoventilation syndrome.
Growth Horm IGF Res 2010, 20:127–133.
121. Ameredes BT, Watchko JF, Daood MJ, Rosas JF, Donahoe MP, Rogers RM:
Growth hormone restores aged diaphragm myosin composition and
performance after chronic denutrition. J Appl Physiol 1999, 87:1253–1259.
122. Laffey J, Kavanagh B: Permissive Hypercapnia. In Principles and Practice of
Mechanical Ventilation. Edited by Tobin MJ. New York: McGraw Hill;
2006:373–392.
123. Sharp JT, Druz WS, Kondragunta VR: Diaphragmatic responses to body
position changes in obese patients with obstructive sleep apnea. Am Rev
Respir Dis 1986, 133:32–37.
124. Zakorsky GS, Wilson B: Sex, girth, waists and hips (what matters for gas
exchange in extreme obesity?). Respir Physiol 2010, 170:120–122.
125. Heinemann F, Budweiser S, Dobroschke J, Pfeifer M: Non-invasive positive
pressure ventilation improves lung volumes in the obesity
hypoventilation syndrome. Respir Med 2007, 101:1229–1235.
126. BaHamman A: Acute ventilatory failure complicating obesity hypoventilation:
update on a ‘critical care syndrome’. Curr Opin Pulm Med 2010, 16:543–551.
127. Steier J, Jolley CJ, Seymour J, Roughton M, Polkey MI, Moxham J: Neural
respiratory drive in obesity. Thorax 2009, 64:719–725.
128. Rapoport DM, Garay SM, Epstein H, Goldring RM: Hypercapnia in the
obstructive sleep apnea syndrome: a reevaluation of the “Pickwickian
syndrome”. Chest 1986, 89:627–635.
129. Berthon-Jones M, Sullivan CE: Time course of change in ventilatory
response to CO2 with long-term CPAP therapy for obstructive sleep
apnea. Am Rev Respir Dis 1987, 135:144–147.
130. Lin CC: Effect of nasal CPAP on ventilatory drive in normocapnic and
hypercapnic patients with obstructive sleep apnoea syndrome. Eur Respir J
1994, 7:2005–2010.
131. De Lucas-Ramos P, de Miguel-Diez J, Santacruz-Siminiani A, González-Moro
JM, Buendía-García MJ, Izquierdo-Alonso JL: Benefits at 1 year of nocturnal
intermittent positive pressure ventilation in patients with obesity-
hypoventilation syndrome. Respir Med 2004, 98:961–967.
132. Jokic R, Zintel T, Sridhar G, Gallagher CG, Fitzpatrick MF: Ventilatory
responses to hypercapnia and hypoxia in relatives of patients with the
obesity hypoventilation syndrome. Thorax 2000, 55:940–945.
133. Han F, Chen E, Wei H, He Q, Ding D, Strohl KP: Treatment effects on
carbon dioxide retention in patients with obstructive sleep apnea-
hypopnea syndrome. Chest 2001, 119:1814–1819.
134. Chouri-Pontarollo N, Borel JC, Tamisier R, Wuyam B, Levy P, Pepin JL:
Impaired objective daytime vigilance in obesity-hypoventilation syndrome:
impact of non-invasive ventilation. Chest 2007, 131:148–155.
135. Raurich JM, Rialp G, Ibanez J, Llompart-Pou JA, Ayestaran I: Hypercapnic
respiratory failure in obesity hypoventilation syndrome: CO2 response
and acetazolamide treatment effects. Repir Care 2010, 55(11):1442–1448.
136. Inyushkin AN, Inyushkin EM, Merkulova NA: Respiratory responses to
microinjections of leptin into the solitary tract nucleus. Neurosci Behav
Physiol 2009, 39:231–240.
137. Atwood CW: Sleep-related hypoventilation: the evolving role of leptin.
Chest 2005, 128:1079–1081.
138. Kalra SP: Central leptin insufficiency syndrome: an interactive etiology for
obesity, metabolic and neural diseases and for designing new
therapeutic interventions. Peptides 2008, 29:127–138.
139. O’Donnell CP, Schaub CD, Haines AS, Berkowitz DE, Tankersley CG, Schwartz AR,
Smith PL: Leptin prevents respiratory depression in obesity. Am J Respir Crit
Care Med 1999, 159:1477–1484.
140. Lévy P, Pépin JL, Arnoud C, Tamisier R, Borel JC, Dematteis M, Godin-Ribuot
D, Ribuot C: Intermittent hypoxia and sleep-disordered breathing: current
concepts and perspectives. Eur Respir J 2008, 32:1082–1095.
141. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH,
Lynn RB, Zhang PL, Sinha MK, Considine RV: Decreased cerebrospinal-fluid/
serum leptin ration: a possible mechanism for leptin resistance. Lancet 1996,
348:159–161.
142. Schwartz MW, Peskind E, Raskind M, Boyko EJ, Porte D Jr: Cerebrospinal
fluid leptin levels: relationship to plasma levels and to adiposity in
humans. Nat Med 1996, 2:589–593.
143. Lin CK, Lin CC: Work of breathing and respiratory drive in obesity.
Respirology 2012, 17:402–411.
Verbraecken and McNicholas Respiratory Research 2013, 14:132 Page 17 of 17
http://respiratory-research.com/content/14/1/132144. Polotsky VY, Wilson JA, Smadone MC, Haines AS, Hurn PD, Tankersley GG,
Smith PL, Schwartz AR, O'Donnell CP: Female gender exacerbates
respiratory depression in leptin-deficient obesity. Am J Respir Crit Care
Med 2001, 164:1470–1475.
145. Malli F, Papaioannou AI, Gourgoulianis KI, Daniil Z: The role of leptin in the
respiratory system: an overview. Respir Res 2010, 11(152):1–16.
146. Popko K, Gorska E, Wasik M, Stoklosa A, Plywaczewsi R, Winiarska M,
Gorecka D, Sliwinski P, Demkow U: Frequency of distribution of leptin
receptor gene polymorphism in obstructive sleep apnoea patients.
J Physiol Pharmacol 2007, 58(5):551–561. Pt 2.
147. Campo A, Fruhbeck G, Zulueta JJ, Iriarte J, Seijo LM, Alcaide AB, Galdiz JB,
Salvador J: Hyperleptinemia, respiratory drive and hypercapnic response
in obese patients. Eur Respir J 2007, 30:223–231.
148. Redolfi S, Corda L, La Piana G, Spandrio S, Prometti P, Tantucci C: Long-term
non-invasive ventilation increases chemosensitivity and leptin in obesity
hypoventilation syndrome. Respir Med 2007, 101:1191–1195.
149. Verbraecken J, Willemen M, De Cock W, Wittesaele W, Govaert K,
Van de Heyning P, De Backer W: Influence of long-term CPAP therapy on
CO2 drive in patients with obstructive sleep apnea. Respir Physiol 2000,
123:121–130.
150. Marti-Valeri C, Sabate A, Masdevall C, Dalmau A: Improvement of associated
respiratory problems in morbidly obese patients after open Roux-en-Y
gastric bypass. Obes Surg 2007, 17(8):1102–1110.
151. Chapman KR, Himal HS, Rebuck AS: Ventilatory responses to hypercapnia
and hypoxia in patients with eucapnic morbid obesity before and after
weight loss. Clin Sci (Lond) 1990, 78(6):541–545.
152. Hlavac MC, Cathceside PG, McDonald R, Eckert DJ, Windler S, McEvoy RD:
Hypoxia impairs the arousal response to external resistive loading and
airway occlusion during sleep. Sleep 2006, 29:624–631.
153. Piper AJ: Nocturnal hypoventilation – identifying & treating syndromes.
Indian J Med Res 2010, 131:350–365.
154. Rabec C, de Lucas RP, Veale D: Respiratory complications of obesity.
Arch Bronchoneumol 2011, 47(5):252–261.
155. Hanaoka M, Yu X, Urushihata K, Ota M, Fujimoto K, Kubo K: Leptin and
leptin receptor gene polymorphisms in obstructive sleep apnoea
syndrome. Chest 2008, 133(1):79–85.
156. Fitzpatrick M: Leptin and the obesity hypoventilation syndrome: a leap of
faith? Thorax 2002, 57(1):1–2.
157. Phipps PR, Starritt E, Caterson I, Grunstein RR: Association of serum leptin
with hypoventilation in human obesity. Thorax 2002, 57:75–76.
158. Thut DC, Schwartz AR, Roach D, Wise RA, Permutt S, Smith PL: Tracheal and
neck position influence upper airway airflow dynamics by altering
airway length. J Appl Physiol 1993, 75:2084–2090.
159. Cooper KR, Phillips BA: Effect of short-term sleep loss on breathing. J Appl
Physiol 1982, 53:855–858.
160. Akashiba T, Kawahara S, Kosaka N, Ito D, Saito O, Majima T, Horie T:
Determinants of chronic hypercapnia in Japanese men with obstructive
sleep apnea syndrome. Chest 2002, 121(2):415–421.
161. Mutlu GM, Rubinstein I: The Saga of obstructive sleep apnea syndrome
and daytime hypercapnia. Work in progress. Chest 2005, 127(3):698–699.
162. Sin DD, Jones RL, Man GC: Hypercapnic ventilatory response in patients
with and without obstructive sleep apnea: do age, gender, obesity, and
daytime PaCO(2) matter? Chest 2000, 117(2):454–459.
163. Katawata N, Tatsumi K, Terada J, Tada Y, Tanabe N, Takiguchi Y, Kuriyama T:
Daytime hypercapnia in obstructive sleep apnea syndrome. Chest 2007,
132(6):1832–1838.
164. Mokhlesi B, Kryger MH, Grunstein RR: Assessment and management of patients
with obesity hypoventilation syndrome. Proc Am Thor Soc 2008, 5:218–225.
165. Rapoport D: Obesity hypoventilation syndrome: more than just severe
sleep apnea. Sleep Med Rev 2011, 15(2):77–78.
166. De Miguel DJ, De Lucas RP, Perez Parra JJ, Buendia Garcia MJ, Cubillo Marcos JM,
Gonzalez-Moro JM: Analysis of withdrawal from non-invasive mechanical
ventilation in patients with obesity-hypoventilation syndrome: medium
term results. Arch Bronconeumol 2003, 39:292–297.
167. Lee SD, Nakano H, Farkas GA: Adenosinergic modulation of ventilation in
obese Zucker rats. Obes Res 2005, 13:545–555.
168. Norman RG, Goldring RM, Clain JM, Oppenheimer BW, Charney AN,
Rapoport DM, Berger KI: Transition from acute to chronic hypercapnia in
patients with periodic breathing: predictions from a computer model.
J Appl Physiol 2006, 100:1733–1741.169. Ayappa I, Berger KI, Norman RG, Oppenheimer BW, Rapoport DM, Goldring RM:
Hypercapnia and ventilatory periodicity in obstructive sleep apnea
syndrome. Am J Respir Crit Cared Med 2002, 166:1112–1115.
170. Gifford AH, Leitter JC, Manning HL: Respiratory function in an obese
patient with sleep-disordered breathing. Chest 2010, 138(3):704–715.
171. Berger KI, Goldring RM, Rapoport DM: Obesity hypoventilation syndrome.
Semin Respir Crit Care Med 2009, 30:253–261.
172. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S: Adipokines: molecular links
between obesity and atherosclerosis. Am J Physiol heart Circ Physiol 2005,
288:H2031–H2041.
173. Higashiura K, Ura N, Ohata J, Togashi N, Takagi S, Saitoh S, Murakami H,
Takeaway Y, Shimamoto K: Correlations of adiponectin level with insulin
resistance and atherosclerosis in Japanese male populations.
Clin Endocrinol (Oxf ) 2004, 61:753–759.
174. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S,
Tochino Y, Komuro R, Matsuda M, Shimomura I: Adipose tissue hypoxia in obesity
and its impact on adipocytokine dysregulation. Diabetes 2007, 56:901–911.
175. Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J, Wong L, Hoo RL, Zhang J,
Xu A: Hypoxia dysregulates the production of adiponectin and
plasminogen activator inhibitor-1 independent of reactive oxygen
species in adipocytes. Biochem Biophys Res Commun 2006, 341:549–556.
176. Borel JC, Roux-Lombard P, Tamisier R, Arnaud C, Monneret D, Arnol N,
Baguet JP, Levy P, Pepin JL: Endothelial dysfunction and specific inflammation
in obesity hypoventilation. PLoS One 2009, 4(8):e6733.
177. Basoglu OK, Tasbakan MS: Comparison of clinical characteristics in
patients with obesity hypoventilation syndrome and obese obstructive
sleep apnea syndrome: a case-control study. Clin Respir J 2013. in press.
178. Chau EHL, Lam D, Wong J, Mokhlesi B, Chung F: Obesity hypoventilation
syndrome. A review of epidemiology, pathophysiology, and
perioperative considerations. Anesthesiology 2012, 17(1):188–205.
179. Mokhlesi B, Tulaimat A: Recent advances in obesity hypoventilation
syndrome. Chest 2007, 132(4):1322–1336.
180. Kauppert CA, Dvorak I, Kollert F, Heinemann F, Jörres RA, Pfeifer M, Budweiser
S: Pulmonary hypertension in obesity-hypoventilation syndrome. Respir Med
2013. in press.
181. O’Donoghue FJ, Catcheside PG, Ellis EE, Grunstein RR, Pierce RJ, Rowland LS,
Collins ER, Rochford SE, McEvoy RD: Australian trial of noninvasive
ventilation in chronic airflow limitation investigators: sleep
hypoventilation in hypercapnic chronic obstructive pulmonary disease:
prevalence and associated factors. Eur Respir J 2003, 21:977–984.
182. Young T, Peppard P, Palta M, Hla KM, Finn L, Morgan B, Skatrud J:
Population-based study of sleep-disordered breathing as a risk factor for
hypertension. Arch Intern Med 1997, 157(15):1746–1752.
183. Borel JC, Tamisier R, Gonzalez-Bermejo J, Baguet JP, Monneret D, Arnol N,
Roux-Lombard P, Wuyam B, Levy P, Pépin JL: Noninvasive ventilation in
mild obesity hypoventilation syndrome. A rondomized controlled trial.
Chest 2012, 141(3):692–702.
184. Machado MC, Vollmer WM, Togeiro SM, Bilderback AL, Oliveira MV, Leitão FS,
Queiroga F Jr, Lorenzi-Filho G, Krishnan JA: CPAP and survival in
moderate-to-severe obstructive sleep apnoea syndrome and hypoxaemic
COPD. Eur Respir J 2010, 35(1):132–137.
185. Stanchina ML, Welicky LM, Donat W, Lee D, Corrao W, Malhotra A: Impact
of CPAP use and age on mortality in patients with combined COPD and
obstructive sleep apnea: the overlap syndrome. J Clin Sleep Med 2013,
9(8):767–772.
186. Hida W, Okabe S, Tatsumi K, Kimura H, Akasiba T, Chin K, Ohi M, Nakayama H,
Satoh M, Kuriyama T: Nasal continuous positive airway pressure improves
quality of life in obesity hypoventilation syndrome. Sleep Breath 2003, 7(1):3–12.
187. Berg G, Delaive K, Manfreda J, Walld R, Kryger MH: The use of health-care
resources in obesity- hypoventilation syndrome. Chest 2001, 120(2):377–383.
188. Shaya FT, Lin PJ, Aljawadi MH, Scharf SM: Elevated economic burden in
obstructive lung disease patients with concomitant sleep apnea
syndrome. Sleep Breath 2009, 13(4):317–323.
189. Pepin JL, Borel JC, Janssens JP: Obesity hypoventilation syndrome: an
underdiagnosed and undertreated condition. Am J Respir Crit Care Med
2012, 186(12):1205–1207.
doi:10.1186/1465-9921-14-132
Cite this article as: Verbraecken and McNicholas: Respiratory mechanics
and ventilatory control in overlap syndrome and obesity
hypoventilation. Respiratory Research 2013 14:132.
